- Home
- MCRI vs CGON Comparison
MCRI vs CGON Comparison
Compare MCRI & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- CGON
- Stock Information
- Founded
- MCRI 1972
- CGON 2010
- Country
- MCRI United States
- CGON United States
- Employees
- MCRI N/A
- CGON N/A
- Industry
- MCRI Hotels/Resorts
- CGON
- Sector
- MCRI Consumer Discretionary
- CGON
- Exchange
- MCRI Nasdaq
- CGON NYSE
- Market Cap
- MCRI 1.5B
- CGON 1.3B
- IPO Year
- MCRI 1993
- CGON 2024
- Fundamental
- Price
- MCRI $83.74
- CGON $25.62
- Analyst Decision
- MCRI Hold
- CGON Strong Buy
- Analyst Count
- MCRI 5
- CGON 10
- Target Price
- MCRI $88.60
- CGON $64.00
- AVG Volume (30 Days)
- MCRI 84.8K
- CGON 1.4M
- Earning Date
- MCRI 07-23-2025
- CGON 05-13-2025
- Dividend Yield
- MCRI 1.43%
- CGON N/A
- EPS Growth
- MCRI N/A
- CGON N/A
- EPS
- MCRI 3.96
- CGON N/A
- Revenue
- MCRI $525,923,000.00
- CGON $662,000.00
- Revenue This Year
- MCRI $4.32
- CGON N/A
- Revenue Next Year
- MCRI $2.41
- CGON $12,387.03
- P/E Ratio
- MCRI $21.14
- CGON N/A
- Revenue Growth
- MCRI 3.84
- CGON 224.51
- 52 Week Low
- MCRI $65.57
- CGON $14.80
- 52 Week High
- MCRI $96.11
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- MCRI 62.61
- CGON 53.27
- Support Level
- MCRI $80.40
- CGON $24.79
- Resistance Level
- MCRI $85.16
- CGON $26.60
- Average True Range (ATR)
- MCRI 1.53
- CGON 1.39
- MACD
- MCRI 0.19
- CGON -0.01
- Stochastic Oscillator
- MCRI 70.17
- CGON 48.52
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.